Featured Products
more+
-
Dicobalt octacarbonylCAS:10210-68-1Molecular Formula:Co2(CO)8 -
4,4'-DDTCAS:50-29-3Molecular Formula:C14H9Cl5 -
ReserpineCAS:50-55-5Molecular Formula:C33H40N2O9 -
ChlorpromazineCAS:50-53-3Molecular Formula:C17H19ClN2S -
Quinidine sulfateCAS:50-54-4Molecular Formula:2(C20H24N2O2).H2SO4 -
EstradiolCAS:50-28-2Molecular Formula:C18H24O2 -
EstriolCAS:50-27-1Molecular Formula:C18H24O3 -
PrednisoloneCAS:50-24-8Molecular Formula:C21H28O5
New Arrivals
more+
-
OxytocinCAS:50-56-6Molecular Formula:C43H66N12O12S2 -
N-Acetyl-D-alanineCAS:19436-52-3Molecular Formula:C5H9NO3 -
5-bromo-3,3-dimethyl-2,3-dihydro-1H-isoindol-1-oneCAS:959756-18-4Molecular Formula:C10H10BrNO -
2,2-Dimethylpropylamine hydrochlorideCAS:15925-18-5Molecular Formula:C5H13N.HCl -
(1R,3S,5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acidCAS:1306734-44-0Molecular Formula:C12H19NO4 -
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acidCAS:641569-94-0Molecular Formula:C17H14N4O2 -
(3,3-Difluoro-1-Methyl-cyclobutyl)MethanolCAS:1408076-35-6Molecular Formula:C6H10F2O -
2-hydroxy-4-tetradecyl-1,3,2-dioxaborolaneCAS:84819-41-0Molecular Formula:C16H33BO3
Contact us
Email::[email protected]
News
more+
-
11-26Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye DiseaseAllegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular diseases, today announced that all primary and secondary endpoints of an ex-U.S. vehicle-cont
-
11-15Janssen Licenses "Flexible Antibody" Technology from F-star in New CollabClinical-stage biopharma company F-star Therapeutics announced a new partnership with Janssen Biotech on Wednesday, only one month after presenting an optimistic trial-in-progress update to the public on its tetravalent dual T-cell agonist FS120 at the Eu
-
11-09Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual MeetingWALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced it will present new preclinical data on the company’s lead immuno-oncology program, E
Technical FAQ
more+
Services
Notice